Enanta Pharmaceuticals Files 8-K

TL;DR

Enanta Pharma filed an 8-K on 8/20/25 covering disclosures and financials.

AI Summary

Enanta Pharmaceuticals, Inc. filed an 8-K on August 20, 2025, reporting on events including a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The filing details the company's principal executive offices located at 4 Kingsbury Avenue, Watertown, MA 02472, and its telephone number (617) 607-0800.

Why It Matters

This 8-K filing provides official updates and disclosures from Enanta Pharmaceuticals, Inc. to the SEC, which are important for investors and stakeholders to monitor the company's regulatory compliance and operational events.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain any immediately alarming or significant negative news.

Key Players & Entities

• Enanta Pharmaceuticals, Inc. (company) — Registrant
• August 20, 2025 (date) — Date of earliest event reported
• 4 Kingsbury Avenue, Watertown, Massachusetts 02472 (location) — Principal Executive Offices
• (617) 607-0800 (phone_number) — Registrant's Telephone Number

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select

Filing Documents

• enta-20250820.htm (8-K) — 50KB
• enta-ex99_1.htm (EX-99.1) — 13KB
• img152620751_0.jpg (GRAPHIC) — 33KB
• 0001193125-25-183719.txt ( ) — 217KB
• enta-20250820.xsd (EX-101.SCH) — 24KB
• enta-20250820_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On August 20, 2025, Enanta Pharmaceuticals, Inc. issued a press release regarding the filing of a patent infringement suit against Pfizer Inc. in the Unified Patent Court (UPC) of the European Union. A copy of that press release is being furnished as Exhibit 99.1 and is hereby incorporated by reference. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section and shall not be deemed to be incorporated by reference into any filing of Enanta under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. On August 20, 2025, Enanta announced that it filed suit in the UPC of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets). This enforcement action targets Pfizer's activities in the 18 countries of the European Union that are presently participating in the UPC. The European Patent Office's recent grant of the 265 Patent to Enanta was published in the European Patent Bulletin on August 20, 2025. The 265 Patent is based on Enanta's July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists. The 265 Patent is the European counterpart of U.S. Patent No. 11,358,953 (the '953 Patent) involved in ongoing U.S. litigation between Enanta and Pfizer.

Forward Looking Statements Disclaimer

Forward Looking Statements Disclaimer This Current Report on Form 8-K contains forward-looking statements, including statements with respect to Enanta's filing in the UPC of a suit against Pfizer Inc. and certain of its subsidiaries seeking a determination of liability for use and infringement of Enanta's patent and Enanta's expectations with respect to any further action with respect to such proceedings. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including those covering one or more of its product candidates, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta's senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta's reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in "Risk Factors" in Enanta's Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these st

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release of Enanta Pharmaceuticals, Inc. dated August 20, 2025, entitled "Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ENANTA PHARMACEUTICALS, INC. Date: August 20, 2025 By: /s/ Jay R. Luly, Ph.D. Jay R. Luly, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR